NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis $0.81 -0.02 (-2.46%) Closing price 09/28/2026 04:00 PM EasternExtended Trading$0.81 +0.01 (+1.03%) As of 08:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Lucid Diagnostics Stock (NASDAQ:LUCD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lucid Diagnostics alerts:Sign Up Key Stats Today's Range$0.80▼$0.8350-Day Range$0.78▼$1.0152-Week Range$0.75▼$1.63Volume780,366 shsAverage Volume1.10 million shsMarket Capitalization$163.75 millionP/E RatioN/ADividend YieldN/APrice Target$4.19Consensus RatingModerate Buy Company Overview Lucid Diagnostics Inc. is a medical diagnostics company focused on the detection of precancerous conditions and cancers of the esophagus. The company develops and commercializes diagnostic products intended to support earlier identification of patients at elevated risk, particularly those with Barrett’s esophagus, a condition associated with esophageal cancer. Lucid’s principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with precancerous disease, and EsoCheck, a noninvasive, swallowable balloon capsule and catheter system designed to collect those cells from the esophageal lining. The company markets the products as a complementary approach to conventional screening and surveillance methods. Lucid Diagnostics was established as a subsidiary of PAVmed Inc. and operates through its CLIA-certified laboratory and commercial healthcare activities in the United States. Its products are primarily aimed at physicians, health systems and other healthcare providers seeking expanded screening options for patients who may be at risk of esophageal cancer. Lishan Aklog, M.D., has served as a senior executive of PAVmed and has been associated with Lucid’s leadership.AI Generated. May Contain Errors. Read More Lucid Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreLUCD MarketRank™: Lucid Diagnostics scored higher than 44% of companies evaluated by MarketBeat, and ranked 632nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingLucid Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLucid Diagnostics has a consensus price target of $4.19, representing about 419.7% upside from its current price of $0.81.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 2 research reports in the past 90 days.Read more about Lucid Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.23) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lucid Diagnostics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.78% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 12.48, which indicates bearish sentiment.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.45 News SentimentLucid Diagnostics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.Search Interest7 people have searched for LUCD on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows2 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lucid Diagnostics' insider trading history. Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUCD Stock News HeadlinesCritical Contrast: Lucid Diagnostics (NASDAQ:LUCD) & Alvotech (NASDAQ:ALVO)September 27 at 4:14 AM | americanbankingnews.comLucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysSeptember 22, 2026 | prnewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 29 at 1:00 AM | Porter & Company (Ad)Lucid Diagnostics Earnings Call Balances Progress and RiskAugust 21, 2026 | tipranks.comLucid Diagnostics (LUCD) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | finance.yahoo.comLucid Diagnostics could be 'high in the queue' for Medicare coverage decision, analyst saysAugust 18, 2026 | msn.comLucid Diagnostics Inc. Q2 2026 Earnings Call SummaryAugust 15, 2026 | finance.yahoo.comPAVmed Provides Business Update and Reports Second Quarter 2026 Financial ResultsAugust 14, 2026 | prnewswire.comSee More Headlines LUCD Stock Analysis - Frequently Asked Questions How have LUCD shares performed this year? Lucid Diagnostics' stock was trading at $1.09 at the start of the year. Since then, LUCD stock has decreased by 26.1% and is now trading at $0.8057. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) issued its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.00. The company had revenue of $1.47 million for the quarter, compared to analysts' expectations of $1.43 million. Read the conference call transcript. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an IPO on Tuesday, October 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lucid Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU). Company Calendar Last Earnings8/12/2026Today9/29/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LUCD's financial health is in the Red zone, according to TradeSmith. LUCD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LUCD CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees82Year Founded1991Price Target and Rating Average Price Target for Lucid Diagnostics$4.19 High Price Target$9.25 Low Price Target$2.00 Potential Upside/Downside+419.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.01 million Net Margins-959.76% Pretax Margin-959.76% Return on EquityN/A Return on Assets-119.57% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.31 Sales & Book Value Annual Sales$4.71 million Price / Sales34.77 Cash FlowN/A Price / Cash FlowN/A Book Value($0.31) per share Price / Book-2.60Miscellaneous Outstanding Shares203,240,000Free Float189,220,000Market Cap$163.75 million OptionableNo Data Beta1.10 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:LUCD) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
